{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T18:27:43Z","timestamp":1788114463406,"version":"build-2803163510"},"reference-count":90,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T00:00:00Z","timestamp":1777248000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T00:00:00Z","timestamp":1777248000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA014599"],"award-info":[{"award-number":["P30CA014599"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"name":"AbbVie and University of Chicago Collaborative University of Chicago Comer Development Board Jill and John Svoboda"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Targeting the BCL-2 family of proteins, key regulators of cellular apoptosis, with BH3-mimetics has been a major therapeutic goal to overcome cancer cell death resistance. However, beyond their canonical roles in apoptosis, BCL-2 proteins also play vital roles in cellular metabolism, signaling, and, increasingly, immune cell regulation. T cells in particular depend heavily on BCL-2 family proteins during ontogeny and maintenance, yet the broader consequences of pharmacologically inhibiting anti-apoptotic BCL-2 proteins in T cells remain underexplored. Our group has previously demonstrated that BCL-2 inhibition with the BH3-mimetic venetoclax induces gene expression and plasticity changes in murine T cells. Building upon this, we here investigate whether venetoclax-driven T cell reprogramming can be leveraged to enhance adoptive cell therapies, specifically using chimeric antigen receptor (CAR) T cells targeting CD19 as a model system. Our findings reveal that venetoclax treatment during ex vivo expansion of CART cells, prepared from T cells from healthy donors or chemotherapeutically pretreated patients, potently augments antitumor efficacy in a BCL-2-dependent manner. Transcriptomic and functional analyses demonstrate that venetoclax reprograms CART cells by regulating signaling pathways (e.g., IL-2\/STAT5 and PI3K\/AKT) and metabolic programs (e.g., OXPHOS and glycolysis), yielding CART cells with superior fitness and effector functionalities. These results highlight a novel therapeutic approach using anti-apoptotic drugging to enhance the performance of adoptive T cell therapies and support further examination of venetoclax and other BH3-mimetics as immune modulators.<\/jats:p>","DOI":"10.1038\/s41392-026-02655-y","type":"journal-article","created":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T00:02:15Z","timestamp":1777248135000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Therapeutic targeting of BCL-2 during CART cell production augments potency through non-apoptotic adaptive changes"],"prefix":"10.1038","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9009-9897","authenticated-orcid":false,"given":"Nada S.","family":"Aboelella","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5348-799X","authenticated-orcid":false,"given":"Erting","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Asby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua D.","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tony","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sidney","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lishi","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin P.","family":"Kline","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2719-0580","authenticated-orcid":false,"given":"Peter A.","family":"Riedell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0271-4384","authenticated-orcid":false,"given":"Jun","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6776-4695","authenticated-orcid":false,"given":"James L.","family":"LaBelle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,27]]},"reference":[{"key":"2655_CR1","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","volume":"12","author":"D Hanahan","year":"2022","unstructured":"Hanahan, D. Hallmarks of cancer: new dimensions. Cancer Discov. 12, 31\u201346 (2022).","journal-title":"Cancer Discov."},{"key":"2655_CR2","doi-asserted-by":"publisher","first-page":"e1007485","DOI":"10.1371\/journal.pcbi.1007485","volume":"15","author":"SM Konig","year":"2019","unstructured":"Konig, S. M., Rissler, V., Terkelsen, T., Lambrughi, M. & Papaleo, E. Alterations of the interactome of Bcl-2 proteins in breast cancer at the transcriptional, mutational and structural level. PLoS Comput. Biol. 15, e1007485 (2019).","journal-title":"PLoS Comput. Biol."},{"key":"2655_CR3","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1023\/A:1009688706783","volume":"3","author":"G Packham","year":"1998","unstructured":"Packham, G. Mutation of BCL-2 family proteins in cancer. Apoptosis 3, 75\u201382 (1998).","journal-title":"Apoptosis"},{"key":"2655_CR4","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1002\/mco2.36","volume":"1","author":"T Zhang","year":"2020","unstructured":"Zhang, T. et al. Functional impact of cancer patient-associated Bcl-xL mutations. MedComm 1, 328\u2013337 (2020).","journal-title":"MedComm"},{"key":"2655_CR5","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1038\/cdd.2015.50","volume":"22","author":"AR Delbridge","year":"2015","unstructured":"Delbridge, A. R. & Strasser, A. The BCL-2 protein family, BH3-mimetics and cancer therapy. Cell Death Differ 22, 1071\u20131080 (2015).","journal-title":"Cell Death Differ"},{"key":"2655_CR6","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1200\/JCO.18.01580","volume":"37","author":"AP Kater","year":"2019","unstructured":"Kater, A. P. et al. Fixed duration of venetoclax-rituximab in relapsed\/refractory chronic lymphocytic leukemia eradicates minimal residual disease and prolongs survival: post-treatment follow-up of the MURANO phase III study. J. Clin. Oncol. 37, 269\u2013277 (2019).","journal-title":"J. Clin. Oncol."},{"key":"2655_CR7","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1038\/s41591-018-0233-1","volume":"24","author":"DA Pollyea","year":"2018","unstructured":"Pollyea, D. A. et al. Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia. Nat. Med. 24, 1859\u20131866 (2018).","journal-title":"Nat. Med."},{"key":"2655_CR8","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1056\/NEJMoa1713976","volume":"378","author":"JF Seymour","year":"2018","unstructured":"Seymour, J. F. et al. Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia. N. Engl. J. Med. 378, 1107\u20131120 (2018).","journal-title":"N. Engl. J. Med."},{"key":"2655_CR9","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1007\/s40265-016-0596-x","volume":"76","author":"ED Deeks","year":"2016","unstructured":"Deeks, E. D. Venetoclax: first global approval. Drugs 76, 979\u2013987 (2016).","journal-title":"Drugs"},{"key":"2655_CR10","unstructured":"US Food and Drug Administration. FDA Approves Venetoclax for CLL and SLL (US Food and Drug Administration, 2019)."},{"key":"2655_CR11","unstructured":"US Food and Drug Administration. FDA Approves Venetoclax in Combination for AML in Adults (US Food and Drug Administration, 2020)."},{"key":"2655_CR12","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1038\/icb.2017.72","volume":"95","author":"EM Carrington","year":"2017","unstructured":"Carrington, E. M. et al. The life and death of immune cell types: the role of BCL-2 anti-apoptotic molecules. Immunol. Cell Biol. 95, 870\u2013877 (2017).","journal-title":"Immunol. Cell Biol."},{"key":"2655_CR13","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1038\/nri1568","volume":"5","author":"A Strasser","year":"2005","unstructured":"Strasser, A. The role of BH3-only proteins in the immune system. Nat. Rev. Immunol. 5, 189\u2013200 (2005).","journal-title":"Nat. Rev. Immunol."},{"key":"2655_CR14","doi-asserted-by":"publisher","first-page":"521","DOI":"10.4049\/jimmunol.181.1.521","volume":"181","author":"I Dzhagalov","year":"2008","unstructured":"Dzhagalov, I., Dunkle, A. & He, Y. W. The anti-apoptotic Bcl-2 family member Mcl-1 promotes T lymphocyte survival at multiple stages. J. Immunol. 181, 521\u2013528 (2008).","journal-title":"J. Immunol."},{"key":"2655_CR15","doi-asserted-by":"publisher","first-page":"3374","DOI":"10.1038\/s41418-020-0585-1","volume":"27","author":"CE Teh","year":"2020","unstructured":"Teh, C. E. et al. MCL-1 is essential for survival but dispensable for metabolic fitness of FOXP3(+) regulatory T cells. Cell Death Differ. 27, 3374\u20133385 (2020).","journal-title":"Cell Death Differ."},{"key":"2655_CR16","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.jaut.2011.12.008","volume":"38","author":"D Tischner","year":"2012","unstructured":"Tischner, D. et al. Defective cell death signalling along the Bcl-2 regulated apoptosis pathway compromises Treg cell development and limits their functionality in mice. J. Autoimmun. 38, 59\u201369 (2012).","journal-title":"J. Autoimmun."},{"key":"2655_CR17","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1084\/jem.20070618","volume":"204","author":"S Wojciechowski","year":"2007","unstructured":"Wojciechowski, S. et al. Bim\/Bcl-2 balance is critical for maintaining naive and memory T cell homeostasis. J. Exp. Med. 204, 1665\u20131675 (2007).","journal-title":"J. Exp. Med."},{"key":"2655_CR18","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1038\/cdd.2017.30","volume":"24","author":"EM Carrington","year":"2017","unstructured":"Carrington, E. M. et al. Anti-apoptotic proteins BCL-2, MCL-1 and A1 summate collectively to maintain survival of immune cell populations both in vitro and in vivo. Cell Death Differ. 24, 878\u2013888 (2017).","journal-title":"Cell Death Differ."},{"key":"2655_CR19","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1038\/s41418-022-00987-0","volume":"29","author":"K Brinkmann","year":"2022","unstructured":"Brinkmann, K., Ng, A. P., de Graaf, C. A. & Strasser, A. What can we learn from mice lacking pro-survival BCL-2 proteins to advance BH3 mimetic drugs for cancer therapy? Cell Death Differ. 29, 1079\u20131093 (2022).","journal-title":"Cell Death Differ."},{"key":"2655_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/1755-8794-1-53","volume":"1","author":"M Wang","year":"2008","unstructured":"Wang, M., Windgassen, D. & Papoutsakis, E. T. A global transcriptional view of apoptosis in human T-cell activation. BMC Med. Genomics 1, 53 (2008).","journal-title":"BMC Med. Genomics"},{"key":"2655_CR21","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1158\/2159-8290.CD-19-0759","volume":"11","author":"FJ Kohlhapp","year":"2021","unstructured":"Kohlhapp, F. J. et al. Venetoclax increases intratumoral effector T cells and antitumor efficacy in combination with immune checkpoint blockade. Cancer Discov. 11, 68\u201379 (2021).","journal-title":"Cancer Discov."},{"key":"2655_CR22","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1182\/blood.2020009081","volume":"138","author":"JB Lee","year":"2021","unstructured":"Lee, J. B. et al. Venetoclax enhances T cell-mediated antileukemic activity by increasing ROS production. Blood 138, 234\u2013245 (2021).","journal-title":"Blood"},{"key":"2655_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01064-0","volume":"14","author":"J Nagasaki","year":"2024","unstructured":"Nagasaki, J. et al. T cells with high BCL-2 expression induced by venetoclax impact anti-leukemic immunity graft-versus-leukemia effects. Blood Cancer J. 14, 79 (2024).","journal-title":"Blood Cancer J."},{"key":"2655_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-021-04285-4","volume":"12","author":"LM Ludwig","year":"2021","unstructured":"Ludwig, L. M. et al. Venetoclax imparts distinct cell death sensitivity and adaptivity patterns in T cells. Cell Death Dis. 12, 1005 (2021).","journal-title":"Cell Death Dis."},{"key":"2655_CR25","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1158\/2326-6066.CIR-23-0344","volume":"12","author":"R Liao","year":"2024","unstructured":"Liao, R. et al. Venetoclax induces BCL-2-dependent Treg to TH17 plasticity to enhance the antitumor efficacy of anti-PD-1 checkpoint blockade. Cancer. Immunol. Res 12, 1074\u20131089 (2024).","journal-title":"Cancer. Immunol. Res"},{"key":"2655_CR26","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1038\/cgt.2013.35","volume":"20","author":"H Karlsson","year":"2013","unstructured":"Karlsson, H. et al. Combining CAR T cells and the Bcl-2 family apoptosis inhibitor ABT-737 for treating B-cell malignancy. Cancer Gene Ther. 20, 386\u2013393 (2013).","journal-title":"Cancer Gene Ther."},{"key":"2655_CR27","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adk7640","volume":"16","author":"F Korell","year":"2024","unstructured":"Korell, F. et al. Comparative analysis of Bcl-2 family protein overexpression in CAR T cells alone and in combination with BH3 mimetics. Sci. Transl. Med. 16, eadk7640 (2024).","journal-title":"Sci. Transl. Med."},{"key":"2655_CR28","doi-asserted-by":"publisher","first-page":"2372","DOI":"10.1158\/2159-8290.CD-21-1026","volume":"12","author":"YG Lee","year":"2022","unstructured":"Lee, Y. G. et al. Modulation of BCL-2 in both T cells and tumor cells to enhance chimeric antigen receptor T-cell immunotherapy against cancer. Cancer Discov. 12, 2372\u20132391 (2022).","journal-title":"Cancer Discov."},{"key":"2655_CR29","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.608167","volume":"11","author":"M Yang","year":"2020","unstructured":"Yang, M. et al. Pre-sensitization of malignant B cells through venetoclax significantly improves the cytotoxic efficacy of CD19.CAR-T cells. Front. Immunol. 11, 608167 (2020).","journal-title":"Front. Immunol."},{"key":"2655_CR30","doi-asserted-by":"crossref","unstructured":"Ding, Z. C. et al. Persistent STAT5 activation reprograms the epigenetic landscape in CD4(+) T cells to drive polyfunctionality and antitumor immunity. Sci. Immunol. 5, eaba5962 (2020).","DOI":"10.1126\/sciimmunol.aba5962"},{"key":"2655_CR31","doi-asserted-by":"publisher","first-page":"3875","DOI":"10.1182\/blood-2010-01-265041","volume":"116","author":"JN Kochenderfer","year":"2010","unstructured":"Kochenderfer, J. N., Yu, Z., Frasheri, D., Restifo, N. P. & Rosenberg, S. A. Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells. Blood 116, 3875\u20133886 (2010).","journal-title":"Blood"},{"key":"2655_CR32","doi-asserted-by":"publisher","first-page":"S149","DOI":"10.1038\/onc.2009.52","volume":"27","author":"T Ni Chonghaile","year":"2008","unstructured":"Ni Chonghaile, T. & Letai, A. Mimicking the BH3 domain to kill cancer cells. Oncogene 27, S149\u2013S157 (2008).","journal-title":"Oncogene"},{"key":"2655_CR33","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/s41397-024-00359-6","volume":"24","author":"Y Li","year":"2024","unstructured":"Li, Y. et al. Plasma concentrations of venetoclax and pharmacogenetics correlated with drug efficacy in treatment naive leukemia patients: a retrospective study. Pharmacogenomics J 24, 37 (2024).","journal-title":"Pharmacogenomics J"},{"key":"2655_CR34","doi-asserted-by":"crossref","unstructured":"Aboelella, N. S. et al. Indomethacin-induced oxidative stress enhances death receptor 5 signaling and sensitizes tumor cells to adoptive T-cell therapy. J. Immunother. Cancer 10, e004938 (2022).","DOI":"10.1136\/jitc-2022-004938"},{"key":"2655_CR35","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1016\/j.medj.2022.05.001","volume":"3","author":"F Korell","year":"2022","unstructured":"Korell, F., Berger, T. R. & Maus, M. V. Understanding CAR T cell-tumor interactions: paving the way for successful clinical outcomes. Med 3, 538\u2013564 (2022).","journal-title":"Med"},{"key":"2655_CR36","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1158\/2159-8290.CD-19-0813","volume":"10","author":"N Singh","year":"2020","unstructured":"Singh, N. et al. Impaired death receptor signaling in leukemia causes antigen-independent resistance by inducing CAR T-cell dysfunction. Cancer Discov. 10, 552\u2013567 (2020).","journal-title":"Cancer Discov."},{"key":"2655_CR37","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-017-3383-5","volume":"17","author":"SK Tahir","year":"2017","unstructured":"Tahir, S. K. et al. Potential mechanisms of resistance to venetoclax and strategies to circumvent it. BMC Cancer 17, 399 (2017).","journal-title":"BMC Cancer"},{"key":"2655_CR38","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1158\/2159-8290.CD-18-1119","volume":"9","author":"P Blombery","year":"2019","unstructured":"Blombery, P. et al. Acquisition of the recurrent Gly101Val mutation in BCL2 confers resistance to venetoclax in patients with progressive chronic lymphocytic leukemia. Cancer Discov. 9, 342\u2013353 (2019).","journal-title":"Cancer Discov."},{"key":"2655_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-10363-1","volume":"10","author":"RW Birkinshaw","year":"2019","unstructured":"Birkinshaw, R. W. et al. Structures of BCL-2 in complex with venetoclax reveal the molecular basis of resistance mutations. Nat. Commun. 10, 2385 (2019).","journal-title":"Nat. Commun."},{"key":"2655_CR40","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1158\/2159-8290.CD-18-0387","volume":"8","author":"S Caenepeel","year":"2018","unstructured":"Caenepeel, S. et al. AMG 176, a aelective MCL1 inhibitor, is effective in hematologic cancer models alone and in combination with established therapies. Cancer Discov. 8, 1582\u20131597 (2018).","journal-title":"Cancer Discov."},{"key":"2655_CR41","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/nature19830","volume":"538","author":"A Kotschy","year":"2016","unstructured":"Kotschy, A. et al. The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models. Nature 538, 477\u2013482 (2016).","journal-title":"Nature"},{"key":"2655_CR42","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1182\/blood.2021011597","volume":"139","author":"CR Funk","year":"2022","unstructured":"Funk, C. R. et al. PI3Kdelta\/gamma inhibition promotes human CART cell epigenetic and metabolic reprogramming to enhance antitumor cytotoxicity. Blood 139, 523\u2013537 (2022).","journal-title":"Blood"},{"key":"2655_CR43","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1038\/s41375-017-0008-6","volume":"32","author":"W Zheng","year":"2018","unstructured":"Zheng, W. et al. PI3K orchestration of the in vivo persistence of chimeric antigen receptor-modified T cells. Leukemia 32, 1157\u20131167 (2018).","journal-title":"Leukemia"},{"key":"2655_CR44","doi-asserted-by":"publisher","first-page":"16601","DOI":"10.1073\/pnas.1003457107","volume":"107","author":"TW Hand","year":"2010","unstructured":"Hand, T. W. et al. Differential effects of STAT5 and PI3K\/AKT signaling on effector and memory CD8 T-cell survival. Proc. Natl. Acad. Sci. USA 107, 16601\u201316606 (2010).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2655_CR45","doi-asserted-by":"publisher","first-page":"e17","DOI":"10.1371\/journal.pbio.1000017","volume":"7","author":"V Calleja","year":"2009","unstructured":"Calleja, V., Laguerre, M., Parker, P. J. & Larijani, B. Role of a novel PH-kinase domain interface in PKB\/Akt regulation: structural mechanism for allosteric inhibition. PLoS Biol. 7, e17 (2009).","journal-title":"PLoS Biol."},{"key":"2655_CR46","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1038\/s41375-017-0005-9","volume":"32","author":"B Wingelhofer","year":"2018","unstructured":"Wingelhofer, B. et al. Pharmacologic inhibition of STAT5 in acute myeloid leukemia. Leukemia 32, 1135\u20131146 (2018).","journal-title":"Leukemia"},{"key":"2655_CR47","doi-asserted-by":"crossref","unstructured":"Klebanoff, C. A. et al. Inhibition of AKT signaling uncouples T cell differentiation from expansion for receptor-engineered adoptive immunotherapy. JCI Insight 2, e95103 (2017).","DOI":"10.1172\/jci.insight.95103"},{"key":"2655_CR48","doi-asserted-by":"publisher","first-page":"e007002","DOI":"10.1136\/jitc-2023-007002","volume":"11","author":"V Mehra","year":"2023","unstructured":"Mehra, V. et al. AKT inhibition generates potent polyfunctional clinical grade AUTO1 CAR T-cells, enhancing function and survival. J. Immunother. Cancer 11, e007002 (2023).","journal-title":"J. Immunother. Cancer"},{"key":"2655_CR49","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1038\/s41423-020-0365-3","volume":"18","author":"N Dumauthioz","year":"2021","unstructured":"Dumauthioz, N. et al. Enforced PGC-1alpha expression promotes CD8 T cell fitness, memory formation and antitumor immunity. Cell Mol. Immunol. 18, 1761\u20131771 (2021).","journal-title":"Cell Mol. Immunol."},{"key":"2655_CR50","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.immuni.2011.12.007","volume":"36","author":"GJ van der Windt","year":"2012","unstructured":"van der Windt, G. J. et al. Mitochondrial respiratory capacity is a critical regulator of CD8+ T cell memory development. Immunity 36, 68\u201378 (2012).","journal-title":"Immunity"},{"key":"2655_CR51","first-page":"3","volume":"44","author":"RZ Zhao","year":"2019","unstructured":"Zhao, R. Z., Jiang, S., Zhang, L. & Yu, Z. B. Mitochondrial electron transport chain, ROS generation and uncoupling (review). Int. J. Mol. Med. 44, 3\u201315 (2019).","journal-title":"Int. J. Mol. Med."},{"key":"2655_CR52","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.652687","volume":"12","author":"HY Peng","year":"2021","unstructured":"Peng, H. Y. et al. Metabolic reprogramming and reactive oxygen species in T cell immunity. Front. Immunol. 12, 652687 (2021).","journal-title":"Front. Immunol."},{"key":"2655_CR53","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1016\/j.immuni.2016.02.023","volume":"44","author":"OU Kawalekar","year":"2016","unstructured":"Kawalekar, O. U. et al. Distinct signaling of coreceptors regulates specific metabolism pathways and impacts memory development in CAR T cells. Immunity 44, 712 (2016).","journal-title":"Immunity"},{"key":"2655_CR54","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-10023-4","volume":"10","author":"N Jones","year":"2019","unstructured":"Jones, N. et al. Akt and STAT5 mediate naive human CD4+ T-cell early metabolic response to TCR stimulation. Nat. Commun. 10, 2042 (2019).","journal-title":"Nat. Commun."},{"key":"2655_CR55","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abl9467","volume":"7","author":"AV Villarino","year":"2022","unstructured":"Villarino, A. V. et al. A central role for STAT5 in the transcriptional programing of T helper cell metabolism. Sci. Immunol. 7, eabl9467 (2022).","journal-title":"Sci. Immunol."},{"key":"2655_CR56","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.1182\/blood-2007-06-096297","volume":"111","author":"JA Wofford","year":"2008","unstructured":"Wofford, J. A., Wieman, H. L., Jacobs, S. R., Zhao, Y. & Rathmell, J. C. IL-7 promotes Glut1 trafficking and glucose uptake via STAT5-mediated activation of Akt to support T-cell survival. Blood 111, 2101\u20132111 (2008).","journal-title":"Blood"},{"key":"2655_CR57","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101580","volume":"5","author":"Y Wang","year":"2024","unstructured":"Wang, Y. et al. Venetoclax acts as an immunometabolic modulator to potentiate adoptive NK cell immunotherapy against leukemia. Cell Rep. Med. 5, 101580 (2024).","journal-title":"Cell Rep. Med."},{"key":"2655_CR58","doi-asserted-by":"publisher","first-page":"2448","DOI":"10.1158\/2159-8290.CD-22-1338","volume":"13","author":"L Zhao","year":"2023","unstructured":"Zhao, L. et al. BCL2 inhibition reveals a dendritic cell-specific immune checkpoint that controls tumor immunosurveillance. Cancer Discov. 13, 2448\u20132469 (2023).","journal-title":"Cancer Discov."},{"key":"2655_CR59","doi-asserted-by":"publisher","first-page":"3151","DOI":"10.1158\/1078-0432.CCR-23-0415","volume":"29","author":"C Saygin","year":"2023","unstructured":"Saygin, C. et al. Dual targeting of apoptotic and signaling pathways in T-lineage acute lymphoblastic leukemia. Clin. Cancer Res. 29, 3151\u20133161 (2023).","journal-title":"Clin. Cancer Res."},{"key":"2655_CR60","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2022.101354","volume":"18","author":"K Yamatani","year":"2022","unstructured":"Yamatani, K. et al. Inhibition of BCL2A1 by STAT5 inactivation overcomes resistance to targeted therapies of FLT3-ITD\/D835 mutant AML. Transl. Oncol. 18, 101354 (2022).","journal-title":"Transl. Oncol."},{"key":"2655_CR61","doi-asserted-by":"publisher","first-page":"5034","DOI":"10.1182\/blood-2008-12-196055","volume":"114","author":"G Yoshimoto","year":"2009","unstructured":"Yoshimoto, G. et al. FLT3-ITD up-regulates MCL-1 to promote survival of stem cells in acute myeloid leukemia via FLT3-ITD-specific STAT5 activation. Blood 114, 5034\u20135043 (2009).","journal-title":"Blood"},{"key":"2655_CR62","doi-asserted-by":"publisher","first-page":"e1171445","DOI":"10.1080\/2162402X.2016.1171445","volume":"5","author":"ZC Ding","year":"2016","unstructured":"Ding, Z. C. et al. IL-7 signaling imparts polyfunctionality and stemness potential to CD4(+) T cells. Oncoimmunology 5, e1171445 (2016).","journal-title":"Oncoimmunology"},{"key":"2655_CR63","doi-asserted-by":"publisher","first-page":"2116","DOI":"10.4049\/jimmunol.1000842","volume":"185","author":"P Tripathi","year":"2010","unstructured":"Tripathi, P. et al. STAT5 is critical to maintain effector CD8+ T cell responses. J. Immunol. 185, 2116\u20132124 (2010).","journal-title":"J. Immunol."},{"key":"2655_CR64","doi-asserted-by":"publisher","first-page":"2699","DOI":"10.1016\/j.immuni.2023.11.005","volume":"56","author":"JC Beltra","year":"2023","unstructured":"Beltra, J. C. et al. Stat5 opposes the transcription factor Tox and rewires exhausted CD8(+) T cells toward durable effector-like states during chronic antigen exposure. Immunity 56, 2699\u20132718.e2611 (2023).","journal-title":"Immunity"},{"key":"2655_CR65","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1182\/bloodadvances.2017011254","volume":"2","author":"CT Petersen","year":"2018","unstructured":"Petersen, C. T. et al. Improving T-cell expansion and function for adoptive T-cell therapy using ex vivo treatment with PI3Kdelta inhibitors and VIP antagonists. Blood Adv. 2, 210\u2013223 (2018).","journal-title":"Blood Adv."},{"key":"2655_CR66","first-page":"2379","volume":"9","author":"Q Zhang","year":"2019","unstructured":"Zhang, Q. et al. Akt inhibition at the initial stage of CAR-T preparation enhances the CAR-positive expression rate, memory phenotype and in vivo efficacy. Am. J. Cancer Res. 9, 2379\u20132396 (2019).","journal-title":"Am. J. Cancer Res."},{"key":"2655_CR67","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.3389\/fimmu.2017.01221","volume":"8","author":"JS Bowers","year":"2017","unstructured":"Bowers, J. S. et al. PI3Kdelta inhibition enhances the antitumor fitness of adoptively transferred CD8(+) T cells. Front. Immunol. 8, 1221 (2017).","journal-title":"Front. Immunol."},{"key":"2655_CR68","doi-asserted-by":"publisher","first-page":"5301","DOI":"10.4049\/jimmunol.179.8.5301","volume":"179","author":"HM Lockyer","year":"2007","unstructured":"Lockyer, H. M., Tran, E. & Nelson, B. H. STAT5 is essential for Akt\/p70S6 kinase activity during IL-2-induced lymphocyte proliferation. J. Immunol. 179, 5301\u20135308 (2007).","journal-title":"J. Immunol."},{"key":"2655_CR69","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.canlet.2020.12.004","volume":"500","author":"H Rostamian","year":"2021","unstructured":"Rostamian, H. et al. A metabolic switch to memory CAR T cells: implications for cancer treatment. Cancer Lett. 500, 107\u2013118 (2021).","journal-title":"Cancer Lett."},{"key":"2655_CR70","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s40164-024-00535-1","volume":"13","author":"A Van der Vreken","year":"2024","unstructured":"Van der Vreken, A. et al. Fueling CARs: metabolic strategies to enhance CAR T-cell therapy. Exp. Hematol. Oncol. 13, 66 (2024).","journal-title":"Exp. Hematol. Oncol."},{"key":"2655_CR71","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1038\/nature08097","volume":"460","author":"EL Pearce","year":"2009","unstructured":"Pearce, E. L. et al. Enhancing CD8 T-cell memory by modulating fatty acid metabolism. Nature 460, 103\u2013107 (2009).","journal-title":"Nature"},{"key":"2655_CR72","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-021-03165-x","volume":"19","author":"M Zhang","year":"2021","unstructured":"Zhang, M. et al. Optimization of metabolism to improve efficacy during CAR-T cell manufacturing. J. Transl. Med. 19, 499 (2021).","journal-title":"J. Transl. Med."},{"key":"2655_CR73","doi-asserted-by":"crossref","unstructured":"Lontos, K. et al. Metabolic reprogramming via an engineered PGC-1alpha improves human chimeric antigen receptor T-cell therapy against solid tumors. J. Immunother. Cancer 11, e006522 (2023).","DOI":"10.1136\/jitc-2022-006522"},{"key":"2655_CR74","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1016\/j.bbamcr.2013.01.021","volume":"1833","author":"B Bonneau","year":"2013","unstructured":"Bonneau, B., Prudent, J., Popgeorgiev, N. & Gillet, G. Non-apoptotic roles of Bcl-2 family: the calcium connection. Biochim. Biophys. Acta 1833, 1755\u20131765 (2013).","journal-title":"Biochim. Biophys. Acta"},{"key":"2655_CR75","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.1158\/2159-8290.CD-20-1677","volume":"11","author":"GM Chen","year":"2021","unstructured":"Chen, G. M. et al. Integrative bulk and single-cell profiling of premanufacture T-cell populations reveals factors mediating long-term persistence of CAR T-cell therapy. Cancer Discov. 11, 2186\u20132199 (2021).","journal-title":"Cancer Discov."},{"key":"2655_CR76","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1158\/2159-8290.CD-18-1314","volume":"9","author":"RK Das","year":"2019","unstructured":"Das, R. K., Vernau, L., Grupp, S. A. & Barrett, D. M. Naive T-cell deficits at diagnosis and after chemotherapy impair cell therapy potential in pediatric cancers. Cancer Discov. 9, 492\u2013499 (2019).","journal-title":"Cancer Discov."},{"key":"2655_CR77","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/s41591-018-0010-1","volume":"24","author":"JA Fraietta","year":"2018","unstructured":"Fraietta, J. A. et al. Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. Nat. Med. 24, 563\u2013571 (2018).","journal-title":"Nat. Med."},{"key":"2655_CR78","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.780442","volume":"12","author":"PH Mehta","year":"2021","unstructured":"Mehta, P. H. et al. T cell fitness and autologous CAR T cell therapy in haematologic malignancy. Front. Immunol. 12, 780442 (2021).","journal-title":"Front. Immunol."},{"key":"2655_CR79","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/978-1-4939-8861-7_5","volume":"1877","author":"LM Ludwig","year":"2019","unstructured":"Ludwig, L. M., Maxcy, K. L. & LaBelle, J. L. Flow cytometry-based detection and analysis of BCL-2 family proteins and mitochondrial outer membrane permeabilization (MOMP). Methods Mol. Biol. 1877, 77\u201391 (2019).","journal-title":"Methods Mol. Biol."},{"key":"2655_CR80","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/s41587-023-01767-y","volume":"42","author":"Y Hao","year":"2024","unstructured":"Hao, Y. et al. Dictionary learning for integrative, multimodal and scalable single-cell analysis. Nat Biotechnol. 42, 293\u2013304 (2024).","journal-title":"Nat Biotechnol."},{"key":"2655_CR81","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.cels.2019.03.003","volume":"8","author":"CS McGinnis","year":"2019","unstructured":"McGinnis, C. S., Murrow, L. M. & Gartner, Z. J. DoubletFinder: doublet detection in single-cell RNA sequencing data using artificial nearest neighbors. Cell Syst. 8, 329\u2013337.e324 (2019).","journal-title":"Cell Syst."},{"key":"2655_CR82","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1038\/s41592-019-0619-0","volume":"16","author":"I Korsunsky","year":"2019","unstructured":"Korsunsky, I. et al. Fast, sensitive and accurate integration of single-cell data with Harmony. Nat. Methods 16, 1289\u20131296 (2019).","journal-title":"Nat. Methods"},{"key":"2655_CR83","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1038\/s41587-020-0439-x","volume":"38","author":"PA Ewels","year":"2020","unstructured":"Ewels, P. A. et al. The nf-core framework for community-curated bioinformatics pipelines. Nat. Biotechnol. 38, 276\u2013278 (2020).","journal-title":"Nat. Biotechnol."},{"key":"2655_CR84","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014).","journal-title":"Genome Biol."},{"key":"2655_CR85","volume":"2","author":"T Wu","year":"2021","unstructured":"Wu, T. et al. clusterProfiler 4.0: a universal enrichment tool for interpreting omics data. Innovation 2, 100141 (2021).","journal-title":"Innovation"},{"key":"2655_CR86","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1089\/omi.2011.0118","volume":"16","author":"G Yu","year":"2012","unstructured":"Yu, G., Wang, L. G., Han, Y. & He, Q. Y. clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS 16, 284\u2013287 (2012).","journal-title":"OMICS"},{"key":"2655_CR87","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA 102, 15545\u201315550 (2005).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2655_CR88","unstructured":"Korotkevich, G. et al. Fast gene set enrichment analysis. Preprint at bioRxiv https:\/\/www.biorxiv.org\/content\/10.1101\/060012v2 (2021)."},{"key":"2655_CR89","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","volume":"1","author":"A Liberzon","year":"2015","unstructured":"Liberzon, A. et al. The molecular signatures database (MSigDB) hallmark gene set collection. Cell Syst. 1, 417\u2013425 (2015).","journal-title":"Cell Syst."},{"key":"2655_CR90","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1093\/nar\/28.1.27","volume":"28","author":"M Kanehisa","year":"2000","unstructured":"Kanehisa, M. & Goto, S. KEGG: Kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 28, 27\u201330 (2000).","journal-title":"Nucleic Acids Res."}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02655-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02655-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02655-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T00:02:18Z","timestamp":1777248138000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02655-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,27]]},"references-count":90,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2655"],"URL":"https:\/\/doi.org\/10.1038\/s41392-026-02655-y","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,27]]},"assertion":[{"value":"22 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.P.K. has served as a consultant for BMS, ADC Therapeutics, BeiGene, GenMab, AbbVie, Seagen, Gilead, and received research support from Merck outside the submitted work. P.A.R. has served as a consultant and\/or advisory board member for AbbVie, Novartis, BMS, ADC Therapeutics, Kite\/Gilead, Pfizer, CVS Caremark, Genmab, BeiGene, Janssen, Pharmacyclics, and Genentech\/Roche. Honoraria from Adaptive Biotechnologies. Research support from BMS, Kite Pharma, Novartis, CRISPR Therapeutics, Calibr, Xencor, Fate Therapeutics, AstraZeneca, Genentech\/Roche, Cellectis, Cargo Therapeutics, and Tessa Therapeutics. J.L.L. has served as a consultant and\/or advisory board member for AbbVie, Pfizer, Vertex, and Newave Pharmaceutical, and received research support from AbbVie, the American Cancer Society, and the Myeloma Solutions Fund outside the submitted work. No disclosures were reported by the other authors.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":">All patients consented to the University of Chicago Institutional Review Board-approved protocols IRB#14-0221-CR009 and IRB #18-0025. All experiments were performed in accordance with relevant guidelines and regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human ethics and consent to participate"}}],"article-number":"155"}}